A synthesis of 102 recently added cannabis articles — key themes, clinical context, and Dr. Caplan’s take.
Natural Approaches to Managing Chronic Inflammation – WorldHealth.net
WHY IT MATTERS: Patients managing chronic inflammatory conditions now have growing scientific rationale to discuss cannabinoid-based options with their physicians, but translating that science into safe, effective protocols still requires careful medical guidance rather than self-directed supplementation. CLINICAL OVERVIEW: The endocannabinoid system is a legitimate and increasingly well-characterized biological network that helps regulate immune tone and inflammatory signaling through receptors distributed throughout immune tissues, the gut, and the central nervous system. Phytocannabinoids such as CBD and THC interact with this system in ways that can modulate cytokine production, microglial activation, and oxidative stress pathways relevant to chronic inflammatory conditions.
Natural Neuroprotection: Exploring the Potential of Non-Psychoactive Cannabinoids
WHY IT MATTERS: Patients and caregivers exploring cannabinoid options for neurological conditions should understand that while the basic science is genuinely promising, the gap between preclinical findings and proven clinical treatments means these approaches are best pursued under informed medical guidance rather than based on headlines alone. CLINICAL OVERVIEW: The endocannabinoid system plays a fundamental role in regulating neuronal health, modulating inflammation, oxidative stress, and cell survival pathways that are central to neurodegenerative disease processes. Non-psychoactive cannabinoids such as CBD, CBG, and CBDV interact with receptors and signaling cascades throughout the central nervous system in ways that may slow or interrupt the progression of conditions like Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury sequelae.
Cannabis use not linked to cognitive decline or dementia in older adults, study finds – leafie
WHY IT MATTERS: Older adults considering cannabis for symptom management can point to this growing body of evidence when discussing cognitive safety concerns with their doctors. CLINICAL OVERVIEW: Emerging research is challenging long-held assumptions about cannabis use and cognitive aging, with data suggesting that older adults who use cannabis do not show accelerated cognitive decline or increased dementia risk compared to non-users. This is clinically relevant given that older adults are one of the fastest-growing segments of cannabis users, often turning to it for pain, sleep, and anxiety management.
Cannabis compounds show promise in fighting fatty liver disease, scientists say – AZERTAC
WHY IT MATTERS: Patients with fatty liver disease or metabolic syndrome may eventually have access to cannabinoid-based therapies as an adjunct treatment option, but only after human clinical trials confirm the safety and efficacy signals seen in early research. CLINICAL OVERVIEW: Emerging preclinical research is examining how non-psychoactive cannabinoids, particularly CBD and CBG, may influence hepatic lipid metabolism and reduce fat accumulation in liver tissue. These compounds appear to interact with endocannabinoid receptors and metabolic pathways involved in fatty acid synthesis and inflammation, offering a potential therapeutic avenue for metabolic-associated steatotic liver disease.
Israeli researchers find cannabis compounds could lead to 1st drug for fatty liver disease
WHY IT MATTERS: For the estimated 100 million Americans living with fatty liver disease and no approved medication options, this research opens a credible pharmaceutical pathway that could eventually produce a first-in-class treatment derived from cannabis compounds. CLINICAL OVERVIEW: Researchers in Israel have identified specific cannabinoid compounds that show meaningful activity against non-alcoholic fatty liver disease, a condition affecting hundreds of millions of people worldwide that currently has no approved pharmaceutical treatment. The compounds appear to work through mechanisms involving hepatic fat accumulation, inflammation, and fibrosis pathways, which aligns with what the endocannabinoid system is already known to regulate in metabolic and liver tissue.
Study Finds No Link Between Lifetime Cannabis Use and Cognitive Decline in Older Adults
WHY IT MATTERS: Older adults who use or are considering cannabis for conditions like pain, sleep, or anxiety can discuss this research with their physicians without the added concern that long-term use may increase their risk of cognitive decline or dementia. CLINICAL OVERVIEW: Emerging longitudinal research is adding to a growing body of evidence suggesting that lifetime cannabis use in older adults does not appear to accelerate cognitive decline or meaningfully elevate dementia risk. This is clinically significant because older adults represent one of the fastest-growing demographics of cannabis users, and concerns about neurological harm have historically discouraged both patient use and physician engagement.
Cannabis use not linked to cognitive decline or dementia in older adults, study finds – leafie
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchNeurologyAgingSafety Why This Matters Clinicians may reassure older patients that moderate cannabis use does not...
Israeli researchers find cannabis compounds could lead to 1st drug for fatty liver disease
✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchCBDAging Why This Matters Clinicians treating patients with nonalcoholic fatty liver disease (NAFLD) currently lack...
Study Finds No Link Between Lifetime Cannabis Use and Cognitive Decline in Older Adults
✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. NeurologyResearchAgingSafety Why This Matters Clinicians counseling older adult patients about cannabis use can now reference...